13.04.2022 MEDIQON Group AG  DE0006618309

DGAP-News: MEDIQON Group AG: Investor Base strengthened with 2022 Rights Issue


DGAP-News: MEDIQON Group AG / Key word(s): Corporate Action

13.04.2022 / 17:07
The issuer is solely responsible for the content of this announcement.

MEDIQON Group AG: Investor Base strengthened with 2022 Rights Issue

Further to the 04/07/2022 ad-hoc release, MEDIQON Group AG today announces the successful placing of the 2022 rights issue.

The company raised EUR 41.6m by issuing 3,999,820 new shares. The rights issue was significantly oversubscribed.

Sator Grove Holdings LLC and Mitch Rales, Co-Founder and Chair of the Executive Committee of Danaher Corporation, led a group of long-term investors in backstopping the rights issue by subscribing to the overhang of unsubscribed rights.

Jan-Hendrik Mohr, CEO of MEDIQON Group AG:

"We are pleased to receive a great pro-rata uptake in the rights issue and are happy to see new and existing shareholders increase their investment into MEDIQON. Since transitioning into a holding company in 2019, our platform subsidiaries have shown fantastic growth - both organically and by way of acquisition. The proceeds from the 2022 rights issue will fuel significant growth of our group in the coming months. Since our Investment Agreement in November 2021, the guidance and network that Paul & Rick at Sator Grove have added to our group's development have had a tremendous positive impact on our ability to scale. Looking out on the growth in this next chapter of our group, we are particularly excited to have Mitch Rales join our long-term minded, engaged and supportive group of shareholders."

Paul Buser, Co-Founder and Co-CEO, Sator Grove Holdings LLC:

"It is exciting to see the continued pace of evolution of MEDIQON and its platforms. With this latest rights issue, MEDIQON has strengthened its balance sheet as well as its positioning in Europe as a desired home for high quality companies. Jan and team have cultivated one of the best investor bases globally, and that has only gotten stronger in this capital raise with the addition of Mitch Rales, co-founder of Danaher, one of the most successful companies in the world."

Mitch Rales, Co-Founder and Chair of the Executive Committee, Danaher Corporation:

"I am thrilled to become a meaningful shareholder of MEDIQON. Jan and the team have created a unique opportunity to build a long-term compounding franchise in small recurring revenue businesses. I look forward to watching MEDIQON grow aggressively in the years to come."


MEDIQON will publish its 2021 annual report in May 2022 and we are looking forward to welcoming shareholders at our AGM in Frankfurt in July 2022.

13.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: MEDIQON Group AG
Herzog-Adolph-Strasse 2
61462 Königstein im Taunus
Phone: +49 (0) 6174-9687040
Fax: +49 (0) 6174-9687043
E-mail: [email protected]
Internet: www.mediqon-group.de
ISIN: DE0006618309, DE000A254TL0
WKN: 661830, A254TL
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart
EQS News ID: 1327747

End of News DGAP News Service

1327747  13.04.2022 


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 3,21 2,64 0,10 1,08 28,66 42,07 0,00
EBITDA1,2 0,72 8,99 -0,44 -0,61 6,21 10,50 0,00
EBITDA-Marge3 22,43 340,53 -440,00 -56,48 21,67 24,96
EBIT1,4 0,51 8,65 -5,51 -2,56 0,94 2,51 0,00
EBIT-Marge5 15,89 327,65 -5.510,00 -237,04 3,28 5,97 0,00
Jahresüberschuss1 0,54 7,51 -5,01 -2,27 -2,27 -6,60 0,00
Netto-Marge6 16,82 284,47 -5.010,00 -210,19 -7,92 -15,69 0,00
Cashflow1,7 0,75 7,85 -5,00 -1,13 2,87 5,69 0,00
Ergebnis je Aktie8 0,24 3,04 -1,50 -0,18 0,38 0,05 0,23
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

Chapters Group
WKN Kurs in € Einschätzung Börsenwert in Mio. €
661830 21,000 Kaufen 346,48
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
42,00 17,40 2,41 66,67
3,55 60,86 8,24 36,41
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
0,00 0,00 0,00 09.07.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
29.09.2023 24.05.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
3,95% 26,63% 14,75% 46,85%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MEDIQON Group AG  ISIN: DE0006618309 können Sie bei EQS abrufen

Beteiligungen , 661830 , CHG , XETR:CHG